Literature DB >> 8223834

Changes in renal clearance of furosemide due to changes in renal blood flow and plasma albumin concentration.

P A Sjöström1, B G Kron, B G Odlind.   

Abstract

We have shown that, within therapeutic plasma concentrations, the unbound fraction of furosemide changes in direct proportion to the reciprocal of the plasma albumin concentration (correlation coefficient 0.99). Changes in the albumin concentration were produced by ultrafiltration of human plasma using a haemofiltration filter. Thus, we propose that, when studying changes in the pharmacokinetics of a highly protein bound drug, calculated changes in the unbound fraction offer an alternative to actual measurement of the unbound concentration, which is often difficult. Nine healthy volunteers receiving a continuous furosemide infusion were studied in normovolaemia and after dehydration (-1.4 kg), with and without pretreatment with an angiotensin converting enzyme inhibitor (captopril) or an a1-adrenoceptor blocking agent (prazosin). Significantly larger changes in the renal clearance of furosemide were found that could be explained by changes in the unbound fraction. Following dehydration, the unbound fraction of furosemide was decreased by about 5%, while its renal clearance fell by 27%, 33% and 13% after pretreatment with placebo, captopril and prazosin, respectively. The secretory clearance of the unbound furosemide changed substantially and in parallel with changes in the renal blood flow. It is suggested that changes in the renal clearance and excretion of furosemide and its t1/2 are much more dependent on changes in renal blood flow than on changes in its unbound fraction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8223834     DOI: 10.1007/bf00315494

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  [A simple colorimetric method of inulin determination in renal clearance studies on metabolically normal subjects and diabetics].

Authors:  J FUHR; J KACZMARCZYK; C D KRUTTGEN
Journal:  Klin Wochenschr       Date:  1955-08-01

2.  Renal secretion of [35-S]furosemide and depression by albumin binding.

Authors:  R H Bowman
Journal:  Am J Physiol       Date:  1975-07

3.  Renal transport kinetics of furosemide in the isolated perfused rat kidney.

Authors:  L J Lee; J A Cook; D E Smith
Journal:  J Pharmacokinet Biopharm       Date:  1986-04

4.  Determination of furosemide in blood plasma and its binding to proteins in normal plasma and in plasma from patients with acute renal failure.

Authors:  F Andreasen; P Jakobsen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-07

5.  Influence of fraction unbound upon the renal clearance of furosemide in the isolated perfused rat kidney.

Authors:  S Hall; M Rowland
Journal:  J Pharmacol Exp Ther       Date:  1985-01       Impact factor: 4.030

6.  On the mechanism of acute tolerance to furosemide diuresis.

Authors:  P A Sjöström; B G Odlind; B A Beermann; M Hammarlund-Udenaes
Journal:  Scand J Urol Nephrol       Date:  1988

7.  Effect of plasma protein binding on renal clearance of drugs.

Authors:  G Levy
Journal:  J Pharm Sci       Date:  1980-04       Impact factor: 3.534

8.  Influence of plasma protein binding kinetics on hepatic clearance assessed from a "tube" model and a "well-stirred" model.

Authors:  J A Jansen
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

9.  Renal tubular secretion and effects of furosemide.

Authors:  B Odlind; B Beermann
Journal:  Clin Pharmacol Ther       Date:  1980-06       Impact factor: 6.875

10.  Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis.

Authors:  M M Hammarlund; L K Paalzow; B Odlind
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more
  1 in total

Review 1.  Diuretic dosing in acute decompensated heart failure: lessons from DOSE.

Authors:  Patrick T Campbell; Jason Ryan
Journal:  Curr Heart Fail Rep       Date:  2012-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.